United-Guardian, Inc. — Q2 2013 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2013. The company develops, manufactures, and markets personal-care, pharmaceutical, medical, and specialty industrial products.
Financial performance
| Metric | Q2 2013 | Q2 2012 | First half 2013 | First half 2012 |
|---|---|---|---|---|
| Net sales | $3.629 million | $3.735 million | $7.581 million | $7.624 million |
| Operating income | $1.629 million | $1.722 million | $3.609 million | $3.468 million |
| Net income | $1.343 million | $1.193 million | $2.907 million | $2.422 million |
| Diluted EPS | $0.29 | $0.26 | $0.63 | $0.53 |
| Gross margin | 62.4% | 60.8% | 63.4% | 60.6% |
Q2 sales declined 2.9%; first-half sales declined 0.6%. Higher operating income in the first half reflected lower cost of sales, while Q2 operating income fell 5.4% as operating expenses increased. Net income rose 12.5% in Q2 and 20.0% in the first half, helped substantially by supplier settlement income. Effective tax rate was approximately 33%.
Cash, liquidity, and balance sheet
- At June 30, cash and cash equivalents were $2.104 million and marketable securities were $8.580 million. Current assets were $13.656 million versus current liabilities of $1.297 million; working capital was $12.360 million and the current ratio was 10.53:1.
- Total assets were $14.889 million and stockholders’ equity was $13.464 million. The balance sheet reports no borrowings or other debt.
- First-half operating cash flow was $3.614 million, up from $2.788 million. Investing activities used $1.099 million, primarily reflecting net purchases of marketable securities; dividends used $2.160 million. Cash increased $355,172 during the period.
- First-half dividends were $0.47 per share, compared with $0.42 in 2012. The company reported no interest payments.
Material changes, outlook, and risks
- Product mix: First-half personal-care sales increased 11.9% and medical-product sales increased 22.3%. Pharmaceutical sales fell 82.1% because there were no RENACIDIN sales after inventory was depleted in August 2012. The company’s largest marketing partner, Ashland Specialty Ingredients, contributed substantially to personal-care growth.
- RENACIDIN supply disruption: Production problems at the sole supplier halted availability. The supplier agreed to pay $97,610 per month while the product remains unavailable, subject to production resuming or the supply agreement ending January 20, 2014. Settlement income was $292,830 in Q2 and $585,660 in the first half of 2013; it materially boosted reported earnings.
- Management said the current supplier’s production was then expected to resume in September 2013, potentially allowing sales to restart in October. A new supplier and single-dose product were in development, with FDA approval hoped for by the end of 2014. These were expectations, not assured outcomes.
- Management believed working capital would support operations for at least 12 months. Planned RENACIDIN-related spending included approximately $167,000 for a mold and production equipment, plus at least $150,000 for consulting and FDA-submission work; additional production-batch costs were not quantified. The equipment commitment was estimated at $167,000, of which $57,490 had been paid by June 30.
- Key risks cited include product acceptance and competition, product development and quality, intellectual-property changes, economic and industry conditions, interest rates, and regulatory or legislative changes. The filing reported no legal proceedings or off-balance-sheet arrangements. Disclosure controls were deemed effective, with no material changes in internal control reported.
Important facts for investors to verify
- Whether RENACIDIN production resumed as forecast and whether product sales restarted, including continuity of supply before new-supplier approval.
- Whether the supplier’s monthly settlement payments continued and when they ended; these payments were a significant, potentially temporary contributor to earnings.
- FDA review timing, approval requirements, and total costs for the new supplier and packaging, including unquantified production-batch expenses.
- Whether growth in personal-care and medical products can offset the pharmaceutical sales shortfall, and whether sales to the largest marketing partner remain strong.
- Market value and risk exposure of the $8.580 million investment portfolio, whose unrealized gains declined during the first half.